Last updated: September 6, 2026
Obiltoxaximab, marketed as Anthim, is a U.S.-approved monoclonal antibody for inhalational anthrax. Its commercial model is different from conventional biologics: revenue depends primarily on U.S. government procurement for the Strategic National Stockpile rather than recurring prescriptions, hospital demand, or private insurance coverage.
The product has regulatory value as a biodefense countermeasure, but its commercial market is narrow. Public disclosures do not provide a reliable standalone annual-revenue series for Anthim. The most important financial variables are federal contract awards, stockpile replenishment cycles, manufacturing continuity, and competition from raxibacumab and other anthrax countermeasures.
What is obiltoxaximab and how is Anthim used?
Obiltoxaximab is a fully human monoclonal antibody that binds the protective antigen component of Bacillus anthracis toxins. By blocking protective antigen, it inhibits the cellular entry of lethal factor and edema factor.
The FDA approved Anthim on March 18, 2016, under the Animal Rule for treatment of inhalational anthrax caused by B. anthracis, in combination with appropriate antibacterial drugs, and for prevention of inhalational anthrax when alternative therapies are unavailable or unsuitable. The approval relied primarily on animal efficacy studies and human safety and pharmacokinetic data because controlled human efficacy trials are not feasible for inhalational anthrax [1].
| Product attribute |
Detail |
| Brand |
Anthim |
| Active ingredient |
Obiltoxaximab |
| Product type |
Human monoclonal antibody |
| Target |
Bacillus anthracis protective antigen |
| FDA pathway |
Biologics license application under the Animal Rule |
| Original approval |
March 18, 2016 |
| Primary indication |
Treatment and prevention of inhalational anthrax |
| Core buyer |
U.S. government |
| Principal commercial channel |
Strategic National Stockpile procurement |
| Conventional retail market |
Very limited |
| Biosimilar status |
No publicly identified approved biosimilar |
Anthim is not a routine hospital formulary product. Its value is tied to emergency readiness, federal inventory requirements, and the ability to deliver product rapidly during an anthrax incident.
What is the FDA and Orange Book status of Anthim?
Anthim is an FDA-approved biologic regulated through a biologics license application, not an ordinary small-molecule drug application. The Orange Book is therefore not the primary source for its exclusivity or patent position.
The FDA-approved biologic reference product is identified through the Purple Book framework. A biosimilar applicant would generally pursue a 351(k) application and could challenge relevant patents under the Biologics Price Competition and Innovation Act, rather than filing an ANDA with a Paragraph IV certification [2, 3].
Regulatory exclusivity timeline
| Regulatory right |
Relevant date |
Expected status |
| FDA approval |
March 18, 2016 |
Completed |
| Orphan-drug exclusivity |
March 18, 2023 |
Expired, subject to scope and indication |
| BPCIA reference-product exclusivity |
March 18, 2028 |
Expected to end after 12 years from licensure |
| Patent protection |
Patent-specific |
Must be assessed separately from FDA exclusivity |
| Pediatric exclusivity |
Not identified as a material commercial driver |
No established six-month extension reflected in the core market profile |
The 12-year reference-product exclusivity period is not the same as patent protection. It prevents FDA approval of a competing biosimilar for the applicable period but does not prevent a competitor from developing a product or litigating patent rights.
When does obiltoxaximab lose exclusivity?
The principal biologic data-exclusivity date is expected to be March 18, 2028, based on the 12-year BPCIA period. Orphan exclusivity associated with the original approval reached its nominal seven-year endpoint in March 2023.
That does not mean generic or biosimilar entry will occur automatically in 2028. A biosimilar sponsor would need to establish high similarity, secure FDA approval, address interchangeability if sought, and overcome any enforceable patents. The commercial opportunity would also depend on whether the federal government accepts the biosimilar for stockpile procurement.
For Anthim, patent expiry may be less important than for a high-volume commercial biologic. Government procurement contracts can continue after patent expiration if the product remains strategically preferred, competitively priced, and available at the required scale.
What patents protect obiltoxaximab?
The relevant patent estate is expected to include claims directed to anti-protective-antigen antibodies, antibody sequences, binding characteristics, formulations, pharmaceutical compositions, manufacturing methods, and methods for treating or preventing anthrax.
No Orange Book patent list provides a comprehensive public patent schedule for Anthim. The product’s biologic status means that patent analysis requires review of USPTO records, assignment histories, terminal disclaimers, maintenance fees, continuation applications, and any BPCIA patent-exchange disclosures.
Patent-strength assessment
| Patent category |
Relevance to Anthim |
Commercial significance |
| Antibody composition claims |
Protect the antibody sequence or defined binding properties |
Potentially high if claims cover the commercial molecule directly |
| Epitope or binding claims |
Cover interaction with protective antigen |
Can create design-around issues for biosimilar developers |
| Formulation claims |
Address concentration, stability, excipients, or storage |
Usually narrower than composition claims |
| Method-of-use claims |
Cover treatment or prevention of inhalational anthrax |
Strategic value is limited by the small indication |
| Manufacturing claims |
Cover cell culture, purification, or process controls |
May raise technical barriers but often do not block an independently developed biosimilar process |
| Platform or broad genus claims |
Cover antibody families or related constructs |
Strength depends on written-description and enablement validity |
The strongest potential barrier would be an unexpired composition claim covering the commercial antibody or its exact sequence. Formulation and method-of-use patents would generally create narrower barriers because a biosimilar or competitor may design around them.
Are there Paragraph IV challenges to Anthim?
There is no conventional Paragraph IV pathway for Anthim because Paragraph IV certifications apply to ANDAs for small-molecule drugs listed in the Orange Book. A competing biologic would use the 351(k) biosimilar pathway and could raise patent disputes under the BPCIA.
No publicly established biosimilar litigation involving obiltoxaximab has become a material market event. The absence of a biosimilar challenger is consistent with the product’s small addressable market and government-centered procurement model.
Biosimilar risk
Biosimilar risk is currently low in commercial terms, even though the regulatory exclusivity period approaches its end. A potential entrant would face:
- Small and irregular demand.
- High cost of analytical and nonclinical development.
- Need to demonstrate manufacturing consistency for an emergency-use biologic.
- Limited private-sector reimbursement opportunity.
- Dependence on federal procurement decisions.
- Possible patent disputes involving antibody composition, formulation, and manufacturing claims.
- The risk that stockpile contracts favor the incumbent for continuity and surge capacity.
A biosimilar could still become commercially relevant if federal procurement shifts toward price competition or if Anthim’s supply position weakens.
How does Anthim compare with raxibacumab?
Anthim competes most directly with raxibacumab, marketed as Anthrasil. Raxibacumab is also a monoclonal antibody directed at protective antigen and was approved for inhalational anthrax before Anthim.
| Factor |
Obiltoxaximab, Anthim |
Raxibacumab, Anthrasil |
| Mechanism |
Binds protective antigen |
Binds protective antigen |
| Product class |
Human monoclonal antibody |
Human monoclonal antibody |
| Approval timing |
2016 |
2012 |
| Main market |
Government stockpiling |
Government stockpiling |
| Private demand |
Minimal |
Minimal |
| Differentiation |
Manufacturing, procurement terms, supply reliability, administration profile |
Earlier approval and established stockpile position |
| Substitution risk |
High in government tenders |
High in government tenders |
| Biosimilar threat |
Low near term |
Low near term |
The products are strategic substitutes rather than typical branded competitors. The buyer is primarily evaluating readiness, shelf life, delivery logistics, supply assurance, regulatory status, and total procurement cost.
Antibiotics remain part of the treatment framework and may be used with antitoxin therapy. Anthrax vaccines and other countermeasures also compete for limited biodefense budgets, although they are not direct substitutes in every use case.
What is the financial trajectory for obiltoxaximab?
Anthim’s financial trajectory is best described as contract-driven and episodic.
Development phase
Before approval, Elusys Therapeutics relied heavily on federal biodefense support. BARDA and related government programs helped fund development, manufacturing, and procurement activities. This reduced the private capital burden but also established the product’s dependence on public-sector demand.
Post-approval phase
After FDA approval, the principal commercial opportunity became Strategic National Stockpile procurement. Stockpile purchasing is typically conducted through contracts that can include manufacturing, replenishment, options, surge capacity, and delivery milestones.
Public contract announcements should not be treated as equivalent to recognized product revenue. Contract ceilings may include unexercised options, multi-year periods, or services beyond finished-dose sales. The lack of public standalone product reporting prevents a reliable year-by-year Anthim revenue calculation.
| Financial driver |
Effect on Anthim |
| New stockpile awards |
Creates discrete revenue events |
| Contract renewals |
Supports manufacturing continuity |
| Option exercises |
Can produce irregular annual increases |
| Expiration or nonrenewal |
Creates sharp revenue risk |
| Product expiration |
Drives replenishment demand |
| Manufacturing delays |
Can defer revenue and threaten procurement eligibility |
| Federal budget changes |
Directly affect market size |
| Anthrax preparedness priorities |
Determine long-term demand |
| Competition with Anthrasil |
Pressures contract pricing |
| Private-sector uptake |
Too limited to offset federal concentration |
The product does not have the sales profile of a chronic-care biologic. There is no large recurring patient population, no routine prescription base, and no conventional market-access expansion strategy. The financial asset is the ability to maintain federal eligibility and supply the stockpile at acceptable cost.
Which companies are challenging Anthim?
No company has emerged as a major commercial biosimilar challenger to obiltoxaximab. The primary competitive pressure comes from:
- The manufacturer of Anthrasil, the directly competing anthrax monoclonal antibody.
- Developers of alternative anthrax antibodies or antibody combinations.
- Antibiotic suppliers participating in anthrax treatment procurement.
- Vaccine and biodefense companies competing for federal preparedness budgets.
- Potential future biosimilar developers seeking federal stockpile contracts.
The absence of a major challenger does not eliminate risk. A single competing antitoxin can materially affect pricing because the U.S. government is a concentrated buyer with the ability to shift procurement between qualified products.
What patent litigation and settlement risks affect Anthim?
No major publicly established patent litigation or settlement has reshaped the commercial market for Anthim. The principal legal risks are prospective:
- BPCIA litigation if a biosimilar applicant enters after reference-product exclusivity.
- Patent challenges to antibody composition claims.
- Invalidity attacks based on written description, enablement, anticipation, or obviousness.
- Patent-term disputes involving continuations and terminal disclaimers.
- Ownership or assignment disputes involving development-era antibody patents.
- Procurement protests if the government awards stockpile contracts to a competing product.
A settlement could delay biosimilar entry, but the economic value of a settlement would be constrained by the small market. In contrast with oncology or immunology biologics, a delayed Anthim biosimilar would not preserve billions of dollars in annual commercial sales.
What generic entry risks exist for obiltoxaximab?
Traditional generic entry risk is negligible because obiltoxaximab is a biologic. Biosimilar entry risk is low before the expected 2028 reference-product exclusivity endpoint and moderate thereafter.
A realistic entry scenario would require all of the following:
- A sponsor identifies sufficient federal demand.
- The sponsor develops a highly similar antibody.
- FDA accepts and approves a 351(k) application.
- Patent disputes are resolved or avoided.
- The federal government permits the new product into stockpile procurement.
- The entrant can manufacture at a lower total cost while meeting readiness requirements.
The most likely near-term scenario is continued incumbent supply under federal contracts. The more disruptive scenario is a procurement contest after 2028 that lowers prices without materially expanding the market.
What manufacturing and intellectual-property barriers protect Anthim?
Manufacturing is a meaningful barrier even if patent protection weakens. Anthim requires validated biologic production, purification, formulation, fill-finish, quality testing, cold-chain controls, and regulatory maintenance.
For a biodefense product, the manufacturer must also demonstrate supply reliability during an emergency. Federal buyers may value an established process and qualified facility because a manufacturing interruption could reduce national readiness.
The key barriers are:
- Validated cell-line and upstream processes.
- Consistent antibody potency and purity.
- Stability and shelf-life data.
- Batch-release testing.
- Regulatory comparability after manufacturing changes.
- Specialized fill-finish capacity.
- Government acceptance of alternate manufacturing sites.
- Patent claims covering the antibody or process.
These barriers support incumbent durability but do not guarantee pricing power. Government procurement can impose substantial price discipline.
What is the commercial outlook for Anthim?
Anthim has a defensible strategic role but a limited conventional market. Its outlook depends on the following factors:
| Outlook factor |
Assessment |
| Regulatory status |
Strong; FDA-approved for a high-consequence indication |
| Demand growth |
Low and policy-dependent |
| Revenue visibility |
Moderate when contracts are active, weak between awards |
| Private-market expansion |
Unlikely |
| Biosimilar threat before 2028 |
Low |
| Biosimilar threat after 2028 |
Moderate, subject to federal demand |
| Pricing power |
Limited by government procurement |
| Manufacturing value |
High because continuity and readiness matter |
| Patent value |
Potentially important, but less decisive than regulatory and procurement position |
| Investment profile |
Contract-dependent biodefense asset rather than growth biologic |
Anthim is best valued as a government-backed biodefense franchise with lumpy revenue and strategic manufacturing value. Its principal downside is buyer concentration. Its principal upside is a long-term federal requirement for anthrax countermeasures and replenishment of expiring stockpile inventory.
Key Takeaways
- Obiltoxaximab, marketed as Anthim, is an FDA-approved monoclonal antibody for inhalational anthrax.
- The product’s market is dominated by U.S. government procurement rather than commercial prescriptions.
- The original orphan exclusivity period reached its nominal endpoint in March 2023.
- BPCIA reference-product exclusivity is expected to run through March 18, 2028.
- Paragraph IV litigation is not the relevant pathway because Anthim is a biologic, not an Orange Book small-molecule product.
- No major public biosimilar challenge has materially affected the product.
- Raxibacumab, marketed as Anthrasil, is the principal direct product competitor.
- Public disclosures do not support a reliable standalone annual-revenue series for Anthim.
- Manufacturing continuity, federal contracting, and stockpile replenishment are more important than retail market expansion.
- Post-2028 biosimilar risk is possible but constrained by the small market and government-centered demand.
FAQs
How much revenue does Anthim generate each year?
A reliable standalone annual-revenue figure is not publicly established. Anthim revenue is generally embedded in contract awards and company-level reporting, while contract ceilings may include options and services that are not recognized as product sales in the same period.
Is Anthim covered by the FDA Orange Book?
No. Anthim is a biologic licensed through a BLA. The Purple Book and BPCIA framework are more relevant than the Orange Book and Paragraph IV process.
Can a biosimilar of obiltoxaximab launch in 2028?
A biosimilar could potentially seek approval after the applicable reference-product exclusivity period, subject to FDA approval, patent resolution, and federal procurement acceptance. The end of data exclusivity does not guarantee market entry.
Does Anthim compete with antibiotics?
Yes, but not as a complete substitute. FDA labeling contemplates Anthim use with appropriate antibacterial therapy for treatment of inhalational anthrax. Antibiotics address bacterial infection, while obiltoxaximab neutralizes anthrax toxin activity.
Why is Anthim commercially valuable despite its small patient market?
Its value comes from biodefense readiness. The product can support national stockpile requirements, emergency response capacity, and federal preparedness objectives even when routine clinical demand is minimal.
References
- U.S. Food and Drug Administration. (2016, March 18). FDA approves treatment for inhalational anthrax. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Anthim (obiltoxaximab) prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov
- Administration for Strategic Preparedness and Response. (2024). Strategic National Stockpile and medical countermeasure procurement programs. U.S. Department of Health and Human Services. https://aspr.hhs.gov
- U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009. Public Law 111-148, §7002.
